The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study
Autor: | Carl-Fredrik Westin, Filip Szczepankiewicz, Petr Kudlička, Zora Kikinis, Ofer Pasternak, Jan Lošák, Libor Ustohal, T. Wilson Woo, Martin Jáni, Jarrett Rushmore, Mark Vangel, Marek Kubicki, Tomáš Kašpárek, Elizabeth Rizzoni, Lubomír Vojtíšek, Magdalena Seethaler, Johanna Seitz-Holland, Kang-Ik K. Cho, Carina Heller, Josef Tomandl, Nikos Makris, Olcay Senay Sahin |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male medicine.medical_specialty Hippocampal formation Hippocampus Neuroprotection Correlation 03 medical and health sciences 0302 clinical medicine Text mining Internal medicine Correspondence Neuroplasticity medicine Humans Hippocampus (mythology) Pharmacology medicine.diagnostic_test business.industry Magnetic resonance imaging medicine.disease Magnetic Resonance Imaging 030227 psychiatry body regions Psychiatry and Mental health Endocrinology Matrix Metalloproteinase 9 Schizophrenia Female business 030217 neurology & neurosurgery |
Zdroj: | Neuropsychopharmacology |
ISSN: | 1740-634X 0893-133X |
Popis: | Matrix metalloproteinases 9 (MMP9) are enzymes involved in regulating neuroplasticity in the hippocampus. This, combined with evidence for disrupted hippocampal structure and function in schizophrenia, has prompted our current investigation into the relationship between MMP9 and hippocampal volumes in schizophrenia. 34 healthy individuals (mean age = 32.50, male = 21, female = 13) and 30 subjects with schizophrenia (mean age = 33.07, male = 19, female = 11) underwent a blood draw and T1-weighted magnetic resonance imaging. The hippocampus was automatically segmented utilizing FreeSurfer. MMP9 plasma levels were measured with ELISA. ANCOVAs were conducted to compare MMP9 plasma levels (corrected for age and sex) and hippocampal volumes between groups (corrected for age, sex, total intracranial volume). Spearman correlations were utilized to investigate the relationship between symptoms, medication, duration of illness, number of episodes, and MMP9 plasma levels in patients. Last, we explored the correlation between MMP9 levels and hippocampal volumes in patients and healthy individuals separately. Patients displayed higher MMP9 plasma levels than healthy individuals (F(1, 60) = 21.19, p < 0.0001). MMP9 levels correlated with negative symptoms in patients (R = 0.39, p = 0.035), but not with medication, duration of illness, or the number of episodes. Further, patients had smaller left (F(1,59) = 9.12, p = 0.0040) and right (F(1,59) = 6.49, p = 0.013) hippocampal volumes. Finally, left (R = -0.39, p = 0.034) and right (R = -0.37, p = 0.046) hippocampal volumes correlated negatively with MMP9 plasma levels in patients. We observe higher MMP9 plasma levels in SCZ, associated with lower hippocampal volumes, suggesting involvement of MMP9 in the pathology of SCZ. Future studies are needed to investigate how MMP9 influences the pathology of SCZ over the lifespan, whether the observed associations are specific for schizophrenia, and if a therapeutic modulation of MMP9 promotes neuroprotective effects in SCZ. |
Databáze: | OpenAIRE |
Externí odkaz: |